Apilimod Compositions and Methods for Using Same

Abstract

The present invention relates to methods for treating cancer with apilimod and related compositions and methods.

1 - 23 . (canceled) 
     
     
         24 . A method for treating a refractory or recurrent non-Hodgkin's B cell lymphoma in a human subject in need thereof, the method comprising administering a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, to the subject in a therapeutically effective amount. 
     
     
         25 . The method of  claim 24 , wherein the pharmaceutical composition is an oral dosage form. 
     
     
         26 . The method of  claim 24 , wherein the non-Hodgkin's B cell lymphoma is selected from diffuse large B cell lymphoma (DLBCL), follicular lymphoma, Burkitt's lymphoma, mediastinal B cell lymphoma, and mantle cell lymphoma. 
     
     
         27 . The method of  claim 26 , wherein the non-Hodgkin's B cell lymphoma is DLBCL. 
     
     
         28 . The method of  claim 27 , wherein the DLBCL is DLBCL-GCB. 
     
     
         29 . The method of  claim 26 , wherein the non-Hodgkin's B cell lymphoma is a follicular lymphoma. 
     
     
         30 . The method of  claim 24 , wherein the pharmaceutically acceptable salt is selected from a sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (e.g., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)). 
     
     
         31 . The method of  claim 30 , wherein the pharmaceutically acceptable salt is selected from a chloride, mesylate, fumarate, lactate, maleate, pamoate, phosphate, and tartrate. 
     
     
         32 . The method of  claim 24 , wherein the method comprises administering the apilimod, or pharmaceutically acceptable salt thereof, in combination with at least one additional active agent. 
     
     
         33 . The method of  claim 32 , wherein the at least one additional active agent is administered in the same dosage form as the apilimod, or in a separate dosage form. 
     
     
         34 . The method of  claim 32 , wherein the at least one additional active agent is selected from the group consisting of an alkylating agent, an intercalating agent, a tubulin binding agent, a corticosteroid, and combinations thereof. 
     
     
         35 . The method of  claim 32 , wherein the at least one additional active agent is selected from the group consisting of ibrutinib, rituximab, doxorubicin, prednisolone, vincristine, velcade, and everolimus, and combinations thereof. 
     
     
         36 . The method of  claim 32 , wherein the at least one additional active agent is selected from cyclophosphamide, hydroxydaunorubicin (also referred to as doxorubicin or Adriamycin™) vincristine (also referred to as Oncovin™), prednisone, prednisolone, and combinations thereof. 
     
     
         37 . The method of  claim 32 , wherein the at least one additional active agent is selected from the group consisting of ondansetron, granisetron, dolasetron and palonosetron. 
     
     
         38 . The method of  claim 32 , wherein the at least one additional active agent is selected from the group consisting of pindolol and risperidone. 
     
     
         39 . The method of  claim 32 , wherein the at least one additional active agent is rituximab. 
     
     
         40 . The method of  claim 32 , wherein the at least one additional active agent is ibrutinib.